Denali Therapeutics Inc. (DNLI): Price and Financial Metrics
DNLI Price/Volume Stats
| Current price | $21.53 | 52-week high | $34.78 |
| Prev. close | $21.99 | 52-week low | $21.48 |
| Day low | $21.48 | Volume | 301,523 |
| Day high | $22.54 | Avg. volume | 691,981 |
| 50-day MA | $24.83 | Dividend yield | N/A |
| 200-day MA | $27.21 | Market Cap | 2.96B |
DNLI Stock Price Chart Interactive Chart >
DNLI POWR Grades
- DNLI scores best on the Sentiment dimension, with a Sentiment rank ahead of 77.12% of US stocks.
- DNLI's strongest trending metric is Value; it's been moving up over the last 177 days.
- DNLI ranks lowest in Momentum; there it ranks in the 22nd percentile.
DNLI Stock Summary
- Of note is the ratio of DENALI THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 7.39% of US stocks have a lower such ratio.
- DNLI's price/sales ratio is 8.87; that's higher than the P/S ratio of 89.06% of US stocks.
- As for revenue growth, note that DNLI's revenue has grown 205.2% over the past 12 months; that beats the revenue growth of 97.06% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to DENALI THERAPEUTICS INC are BEAM, NTLA, ARWR, XNCR, and ARVN.
- Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to www.denalitherapeutics.com.
DNLI Valuation Summary
- In comparison to the median Healthcare stock, DNLI's price/earnings ratio is 188.76% lower, now standing at -23.7.
- DNLI's price/sales ratio has moved NA NA over the prior 70 months.
Below are key valuation metrics over time for DNLI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DNLI | 2023-09-22 | 8.9 | 2.6 | -23.7 | -23.1 |
| DNLI | 2023-09-21 | 9.0 | 2.6 | -24.1 | -23.5 |
| DNLI | 2023-09-20 | 8.9 | 2.6 | -23.8 | -23.2 |
| DNLI | 2023-09-19 | 8.8 | 2.6 | -23.6 | -23.1 |
| DNLI | 2023-09-18 | 8.9 | 2.6 | -23.9 | -23.3 |
| DNLI | 2023-09-15 | 9.4 | 2.7 | -25.2 | -24.6 |
DNLI Growth Metrics
- Its year over year cash and equivalents growth rate is now at -75.89%.
- Its year over year revenue growth rate is now at -75.62%.
- Its 3 year price growth rate is now at 1.87%.
The table below shows DNLI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 110.694 | -237.547 | -302.574 |
| 2022-06-30 | 112.42 | -221.935 | -283.863 |
| 2022-03-31 | 82.879 | -233.258 | -285.76 |
| 2021-12-31 | 48.661 | -211.389 | -290.581 |
| 2021-09-30 | 352.962 | 368.02 | 29.565 |
| 2021-06-30 | 357.07 | 409.54 | 55.925 |
DNLI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DNLI has a Quality Grade of C, ranking ahead of 72.1% of graded US stocks.
- DNLI's asset turnover comes in at 0.231 -- ranking 185th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DNLI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.231 | 1 | 0.028 |
| 2021-06-30 | 0.249 | 1 | 0.058 |
| 2021-03-31 | 0.279 | 1 | 0.069 |
| 2020-12-31 | 0.334 | 1 | 0.102 |
| 2020-09-30 | 0.032 | 1 | -0.411 |
| 2020-06-30 | 0.044 | 1 | -0.416 |
DNLI Price Target
For more insight on analysts targets of DNLI, see our DNLI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $85.55 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Denali Therapeutics Inc. (DNLI) Company Bio
Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.
Latest DNLI News From Around the Web
Below are the latest news stories about DENALI THERAPEUTICS INC that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerFlagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corp |
10 Biotech Stocks with Biggest UpsideIn this article, we discuss 12 biotech stocks with biggest upside. If you want to skip our detailed discussion on the recent developments in the biotech industry, you can go directly to 5 Biotech Stocks with Biggest Upside. According to Precedence Research, the size of the biotechnology industry stood at $1.22 trillion at the end […] |
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkersAdditional safety data up to two years of treatment continue to demonstrate that DNL310 is generally well toleratedPreviously reported data showed robust and statistically significant reduction of NfL, a marker of neuronal damage, and positive clinical outcome changes in adaptive behavior, |
Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyInvaio Sciences, a bio platform company accelerating the leap to nature-positive agriculture, today announced that its Citrus Health solution to suppress citrus greening in oranges received approval from the Florida Department of Agriculture and Community Services (FDACS) under section 24(c) of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). |
DNLI Price Returns
| 1-mo | -6.47% |
| 3-mo | -28.19% |
| 6-mo | -1.73% |
| 1-year | -17.10% |
| 3-year | -38.73% |
| 5-year | 1.41% |
| YTD | -22.58% |
| 2022 | -37.65% |
| 2021 | -46.75% |
| 2020 | 380.83% |
| 2019 | -15.68% |
| 2018 | 32.10% |
Continue Researching DNLI
Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...